Total Organic Carbon (TOC) monitoring is key to optimizing wastewater treatment, providing real-time data for effective management of organic contaminants.

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...

ASCO 2025 phase 1b/2 study assessing 9MW2821, nectin-4 antibody drug conjugate, toripalimab in treatment-naïve patients, locally advanced or metastatic urothelial carcinoma.

Nashville-Davidson, June 30, 2025 (GLOBE NEWSWIRE) -- NASHVILLE, Tenn. — Cutting Edge Foot and Ankle Clinic has introduced a new treatment for onychomycosis, more commonly known as toenail ...

Background The KEYNOTE-966 study demonstrated that pembrolizumab combined with chemotherapy is more effective than chemotherapy alone as first-line treatment for patients with advanced biliary tract ...

ASCO 2025 interim analysis from the JAVELIN Bladder Medley phase 2 trial, avelumab + sacituzumab govitecan, avelumab monotherapy, first-line maintenance treatment in patients with advanced urothelial ...

DBS Group, Singapore’s largest lender, is targeting hiring about 40 private bankers this year in Hong Kong and Singapore to cater to wealthy clients in North Asia.

Duquesne Light told Channel 11 that no request was made to shut off the power before the roofing job began, a decision the utility says is not uncommon for this type of work.

Veolia Increases Its Leadership in Hazardous Waste Treatment With Major Investment in New Capacity & Targeted Tuck-ins Acquisitions Delivering on GreenUp ambition to increase hazardous waste ...

Citation: Hagelstein I, Lutz MS, Schmidt M, Heitmann JS, Malenke E, Zhou Y, Clar KL, Kopp H-G, Jung G, Salih HR, Märklin M and Hinterleitner C (2021) Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion ...

Despite the challenges, evolving technologies like focused ultrasound and deep brain stimulation are transforming management strategies and improving quality of life of Parkinson's patients ...